Central Visual ImpairmentGOUSTAVISNCT07707219
A Study of Taste- and Olfactory-Evoked Potentials in Patients With Visual Impairment: Taste, Smell, and Vision
A study testing Taste and smell evaluation and Recording of evoked potentials (EP) in people with Central Visual Impairment and Peripherical Visual Impairment, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
Visual impairment, whether central or peripheral, may influence the plasticity of other sensory modalities, such as taste and smell. Taste-evoked potentials (TEPs) and smell-evoked potentials (SEPs)-methods for analyzing brain activity in response to taste and smell stimuli-allow for the objective assessment of these… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Central Visual Impairment, Peripherical Visual Impairment, Macular Retinal Dystrophy
- What is being tested?
- Taste and smell evaluation and Recording of evoked potentials (EP)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- Sep 2026to Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adult: ≥ 18 years and ≤ 60 years
- Individual who has given oral consent
- Individual who has been fasting (no food, drink, or tobacco) for at least 1 hour prior to PEG and PEO measurement
- No cognitive complaints and normal neurological examination.
- Group of patients with visual impairment:
- Central: documented bilateral macular dystrophy (e.g., Stargardt disease, Best disease) with confirmed central scotoma (CV 24.2, 10.2, or 30.2).
- Peripheral: documented bilateral peripheral retinal dystrophy with confirmed peripheral involvement (CV 30-2 or 24-2).
- Control group: a person with normal vision and no known ophthalmological abnormalities (normal visual acuity and fundus examination) who is precisely matched by sex and smoking status (former smoker who has quit vs. nonsmoker), and approximately matched by age (± 5 years) to a visually impaired participant included in the study.
Who cannot join
- For this group: patients with visual impairments:
- Individuals who are not enrolled in or eligible for a social security program
- Individuals subject to a legal protective measure (guardianship, conservatorship)
- Individuals subject to judicial safeguard measures
- Adults who are legally incapacitated or unable to give informed consent
- Documented COVID-19 infection within the 6 months prior to enrollment
Show all 13Show fewer
- Active smokers (≥1 cigarette per day) or users of any other inhaled substances (water pipe, cannabis, etc.)
- Participants following a sugar-free diet
- Participants with diabetes, of any type
- Participants taking medication (ongoing during the study) that interferes with taste perception • Pregnant or breastfeeding women
- Individuals with neurodegenerative diseases (Parkinson's, Alzheimer's)
- Individuals with braids, dreadlocks, or any other hairstyle that prevents electrodes from being placed in sufficiently precise locations on the scalp.
- Overweight subjects with a BMI ≥ 35 kg/m²
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Chu Dijon Bourgogne
Dijon, 21000
Pierre-Henry GABRIELLE, 03.80.29.37.56 ext. +33, pierrehenry.gabrielle@chu_dijon.fr
About this study
Visual impairment, whether central or peripheral, may influence the plasticity of other sensory modalities, such as taste and smell. Taste-evoked potentials (TEPs) and smell-evoked potentials (SEPs)-methods for analyzing brain activity in response to taste and smell stimuli-allow for the objective assessment of these interactions. This approach has already demonstrated its value in the study of cognitive disorders. This study aims to demonstrate an enhancement of taste and smell capabilities that could compensate for specific visual impairments, particularly in situations involving food choices.
- Conditions
- Central Visual Impairment, Peripherical Visual Impairment, Macular Retinal Dystrophy, Peripherical Macular Dystrophy
- Being tested
- Taste and smell evaluation, Recording of evoked potentials (EP)
- Medical subject headings
- Blindness, Cortical
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Taste and smell evaluationOther
Determination of taste and smell ability scores using standardized methods (ETOC and Taste Strips)
Recording of evoked potentials (EP)Other
A recording of gustatory evoked potentials (GEP) and olfactory evoked potentials (OEP) in response to stimuli consisting of sucrose solution, vanillin, and a combination of the two.
| Study group | Role | What they receive |
|---|---|---|
| Patients with retinal dystrophy and central or peripheral visual field defects | Other | Not described Receives: Other: Taste and smell evaluation; Other: Recording of evoked potentials (EP) |
| Healthy volunteers | Other | Not described Receives: Other: Taste and smell evaluation; Other: Recording of evoked potentials (EP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average latency of PEG (Taste-Evoked Potentials) peaks
Measurement of the mean latency of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).
Measured: At the baseline
Average amplitude of PEG (Taste-Evoked Potentials) peaks
Measurement of the mean amplitude of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).
Measured: At the baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study startSep 2026 (estimated)
- Primary completionSep 2028 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Visual ImpairmentStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07707219
- Sponsor's protocol ID
- GABRIELLE 2026
- Acronym
- GOUSTAVIS
- Status last verified
- Jul 2026
- First submitted
- 2 Jul 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Taste- and Olfactory-Evoked Potentials in Patients With Visual Impairment: Taste, Smell, and Vision
- ClinicalTrials.gov ID
- NCT07707219
- Acronym / sponsor ID
- GOUSTAVIS / GABRIELLE 2026
- Conditions
- Central Visual Impairment, Peripherical Visual Impairment, Macular Retinal Dystrophy, Peripherical Macular Dystrophy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Visual impairment, whether central or peripheral, may influence the plasticity of other sensory modalities, such as taste and smell. Taste-evoked potentials (TEPs) and smell-evoked potentials (SEPs)-methods for analyzing brain activity in response to taste and smell stimuli-allow for the objective assessment of these interactions. This approach has already demonstrated its value in the study of cognitive disorders. This study aims to demonstrate an enhancement of taste and smell capabilities that could compensate for specific visual impairments, particularly in situations involving food choices.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with retinal dystrophy and central or peripheral visual field defects | Other | Other: Taste and smell evaluation, Other: Recording of evoked potentials (EP) |
| Healthy volunteers | Other | Other: Taste and smell evaluation, Other: Recording of evoked potentials (EP) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Adult: ≥ 18 years and ≤ 60 years
- Individual who has given oral consent
- Individual who has been fasting (no food, drink, or tobacco) for at least 1 hour prior to PEG and PEO measurement
- No cognitive complaints and normal neurological examination.
- Group of patients with visual impairment:
Key exclusion criteria (13 listed)
- Individuals who are not enrolled in or eligible for a social security program
- Individuals subject to a legal protective measure (guardianship, conservatorship)
- Individuals subject to judicial safeguard measures
- Adults who are legally incapacitated or unable to give informed consent
- Documented COVID-19 infection within the 6 months prior to enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Taste and smell evaluationDetermination of taste and smell ability scores using standardized methods (ETOC and Taste Strips) | Other | Healthy volunteers, Patients with retinal dystrophy and central or peripheral visual field defects |
| Recording of evoked potentials (EP)A recording of gustatory evoked potentials (GEP) and olfactory evoked potentials (OEP) in response to stimuli consisting of sucrose solution, vanillin, and a combination of the two. | Other | Healthy volunteers, Patients with retinal dystrophy and central or peripheral visual field defects |
Primary outcome
Average latency of PEG (Taste-Evoked Potentials) peaks
Time frame: At the baseline
Measurement of the mean latency of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).
Average amplitude of PEG (Taste-Evoked Potentials) peaks
Time frame: At the baseline
Measurement of the mean amplitude of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
Related trials for Central Visual Impairment
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Diabetic Macular Edema (DME)
Not yet recruiting
Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
Macular Degeneration, Central Visual Impairment
Not yet recruiting
joyVision: The Superiority of Co-design in the Development of a Serious Game for Children With Cerebral Visual Impairment
Cerebral Visual Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Taste and smell evaluation and Recording of evoked potentials (EP) in people with Central Visual Impairment and Peripherical Visual Impairment, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pierre-Henry GABRIELLE (03.80.29.37.56 ext. +33, pierrehenry.gabrielle@chu_dijon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average latency of PEG (Taste-Evoked Potentials) peaks (time frame: At the baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.